

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Use of probiotics in the Helicobacter pylori eradication in Italy: data from the Italian Registry on Helicobacter pylori treatment**

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1713456> since 2019-10-13T11:07:23Z

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

## P1.25

### Use of probiotics in the *Helicobacter pylori* eradication in Italy: data from the Italian Registry on *Helicobacter pylori* treatment

R. Zagari<sup>1</sup>, A. Romiti<sup>1</sup>, G. Fiorini<sup>1</sup>, I. Saracino<sup>1</sup>, D. Ribaldone<sup>2</sup>, A. Panarese<sup>3</sup>, F. Lella<sup>4</sup>, F. Gigliotti<sup>5</sup>, A. Gasbarrini<sup>6</sup>, O. Paoluzi<sup>7</sup>, G. Del Vecchio Blanco<sup>7</sup>, M. Romano<sup>8</sup>, B. Annibale<sup>9</sup>, L. Broglia<sup>10</sup>, R. Catanzaro<sup>11</sup>, C. Marfinati Hervoso<sup>12</sup>, F. Luzza<sup>13</sup>, G. Nardone<sup>14</sup>, R. Conigliaro<sup>15</sup>, R. Cannizzaro<sup>16</sup>, M. Pavoni<sup>1</sup>, B. Vaira<sup>1</sup>, R. Pellicano<sup>2</sup>, M. Ferrara<sup>5</sup>, F. Bazzoli<sup>1</sup>

<sup>1</sup>Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; <sup>10</sup>Unit of Gastroenterology, SS Trinità Hospital, Borgomanero (Novara), Italy; <sup>11</sup>Gastroenterology and Hepatology Service, Internal Medicine Unit, University Hospital "G. Rodolico", Catania, Italy; <sup>12</sup>Division of Gastroenterology, "A. Manzoni" Hospital, Lecco, Italy; <sup>13</sup>Department of Health Sciences, University Magna Græcia, Catanzaro, Italy; <sup>14</sup>Department of Clinical Medicine and Surgery, Hepato-Gastroenterology Unit, University of Naples "Federico II", Naples, Italy; <sup>15</sup>Gastroenterology and Digestive Endoscopy Department, Sant'Agostino Estense Hospital, Baggiovara (Modena), Italy; <sup>16</sup>Department of Gastroenterology, Istituto Nazionale Tumori IRCCS, Aviano (Pordenone), Italy; <sup>2</sup>General and Specialistic Medical Department, Division of Gastroenterology, AOU Città della Salute e della Scienza, Turin, Italy; <sup>3</sup>Department of Gastroenterology and Digestive Endoscopy, IRCCS "Saverio De Bellis", Castellana Grotte (Bari), Italy; <sup>4</sup>Gastroenterology Unit, Policlinico San Pietro, Bergamo, Italy; <sup>5</sup>Gastroenterology and Endoscopic Unit, San Giovanni Calibita-Fatebenefratelli Hospital, Rome, Italy; <sup>6</sup>Gastroenterology Area, Fondazione Policlinico Universitario A Gemelli, Università Cattolica, Rome, Italy; <sup>7</sup>Department of System Medicine, University of Tor Vergata, Rome, Italy; <sup>8</sup>Department of Precision Medicine "F. Magrassi", University of Campania, Naples, Italy; <sup>9</sup>Medical-Surgical Department of Clinical Sciences and Translational Medicine, University Sapienza, Rome, Italy

**Background:** Probiotics may have beneficial effect in reducing adverse events in patients treated for *Helicobacter (H.) pylori* infection; however, data on their use in this setting are scarce.

**Aim:** To investigate the use of probiotic supplementation in the treatment of *H. pylori* infection in clinical practice in Italy.

**Methods:** The "Italian Registry on *H. pylori* treatment" is an online database prospectively registering adult patients prescribed with a treatment for *H. pylori* infection by gastroenterologists in Italy. Data were collected in 17 Centers from June 2017 to May 2019 using the web application REDCap (Research Electronic Data Capture).

**Results:** A total of 1803 patients [1140 (63.5%) females, mean age (SD): 55.4 years (15.1)] were included in the Registry in the study period. Of these, 1699 received one treatment regimen, 101 two regimens and 3 three regimens, with a total of 1910 cases. Probiotics were prescribed in 49.9% (n. 953) of cases: 100% (61/61) with rifabutin triple therapy, 86.4% (472/546) with sequential therapy, 54.2% (77/142) with levofloxacin triple therapy, 46.3% (38/82) with concomitant therapy, 33% (211/641) with bismuth quadruple therapy (Pylera®), 24.1% (90/374) with clarithromycin triple therapy and 21.1% (4/19) with other regimens. The most frequently prescribed probiotic was a combination of *Lactobacillus rhamnosus* and *Bifidobacterium breve* (586, 61.5%), followed by *Lactobacillus casei* DG (118, 12.4%), *Lactobacillus rhamnosus* (85, 8.9%), *Saccaromyces boulardii* (74, 7.8%) and others probiotics (90, 9.4%). Conclusions

Probiotic supplementation is used in half of patients treated for *H. pylori* eradication in Italy. *Lactobacillus* and *Bifidobacterium* are the probiotics most commonly prescribed.

R. Zagari: D. Speakers Bureau/Honoraria (speakers bureau, symposia, and expert witness); Modest; Takeda, Italy. A. Romiti: None. G. Fiorini: None. I. Saracino: None. D. Ribaldone: None. A. Panarese: None. F. Lella: None. F. Gigliotti: None. A. Gasbarrini: None. G. Del Vecchio Blanco: None. M. Romano: None. B. Annibale: None. L. Broglia: None. R. Catanzaro: None. C. Marfinati Hervoso: None. F. Lizza: None. G. Nardone: None. R. Conigliaro: None. R. Cannizzaro: None. M. Pavoni: None. B. Vaira: None. R. Pellicano: None. M. Ferrara: None. F. Bazzoli: None. O. Paoluzi: None.